HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Perrigo’s Generic Loratadine Offerings Could Boost Firm’s Cough/Cold Sales

This article was originally published in The Tan Sheet

Executive Summary

Perrigo's planned introduction of two generic loratadine formulations in early 2004 is expected to improve the firm's lackluster cough/cold sales in the second half of its fiscal year

You may also be interested in...

Leiner Looks To Rule Claritin Equivalent Market With Summer Launches

Leiner Health Products will seek to control the store brand loratadine market with late summer launches of equivalents to Schering-Plough's Claritin RediTabs and D-24

Loratadine Sales Keep Perrigo On Track To Meet Core Business Growth Goals

Perrigo expects to meet its fiscal 2004 target for core business growth despite continued delays in the approval of its 10 mg loratadine tablets (Schering-Plough's Claritin)

Perrigo Expands UK Presence With Vitamin Manufacturer Acquisition

Perrigo's $13 mil. purchase of Peter Black Pharmaceuticals provides the private labeler with a foothold to develop a UK vitamin market presence

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts